The first, the Glioma Actively Personalized Vaccine Consortium (GAPVAC), employed two sets of personalized peptide vaccines designed according to patients tumor mutations, transcriptomic and immuno-peptidomic profiles, and showed that these vaccines were able to elicit sustained CD8+ T cell and CD4+ Th1 responses against neoantigens (76). This evidence concerns the gene CD8A and glioma.